Skip to main content
Glama

Sanctions Screening

by io.github.pipeworx-io

Compare Entities

compare_entities
Read-onlyIdempotent

"Compare X and Y" / "X vs Y" / "X versus Y" / "which is bigger / better / larger / more profitable" / "rank these companies" / "head to head" — side-by-side comparison of 2–5 companies or drugs in ONE parallel call. ALWAYS PREFER over sequential single-pack lookups when comparing entities. type="company" pulls LATEST 10-K revenue + net income + cash + long-term debt from SEC EDGAR/XBRL (off-calendar fiscal years handled correctly — AAPL Sep, NVDA Jan, etc.). type="drug" pulls FAERS adverse-event counts, FDA approval counts, active trial counts. Results sorted by primary metric so "largest" / "most" / "biggest" reads off the top of the response. Returns paired data + pipeworx:// citation URIs per entity. Replaces 8–15 sequential lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valuesYesFor company: 2–5 tickers/CIKs (e.g., ["AAPL","MSFT"]). For drug: 2–5 names (e.g., ["ozempic","mounjaro"]).

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. First observed

TDQS

A5/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already declare readOnlyHint=true, destructiveHint=false, idempotentHint=true, and the description adds valuable behavioral context without contradicting them: data sources (SEC EDGAR/XBRL, FAERS), fiscal year handling, sorting by primary metric, and the inclusion of pipeworx:// citation URIs. This goes beyond annotation basics.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness5/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is dense but every sentence earns its place: it front-loads purpose with examples, then provides usage guidance, technical details, and output expectations. No redundancy or filler; the length is justified by the tool's complexity.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

The description covers purpose, triggers, alternatives, type-specific behavior, sorting, and output format (paired data + citation URIs). Given the tool's complexity and absence of an output schema, this is fully complete for an agent to select and invoke correctly.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema coverage is 100%, but the description significantly enriches parameter meaning. It clarifies what type="company" vs type="drug" returns (specific financial metrics vs trial/adverse-event counts) and what values should contain (tickers/CIKs vs drug names). This is essential semantic detail not present in the schema.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description clearly states the tool performs side-by-side comparisons of 2-5 companies or drugs in one parallel call, with concrete trigger examples ("X vs Y", "which is bigger"). It explicitly distinguishes itself from sequential single-pack lookups and sibling tools like entity_profile, making its purpose unambiguous.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines5/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

It gives explicit when-to-use guidance: "ALWAYS PREFER over sequential single-pack lookups when comparing entities." It also specifies what each entity type does (company vs drug) and even mentions 'Replaces 8–15 sequential lookups,' providing a strong alternative comparison and context for use.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Sanctions Screening toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.8/5.0
Disambiguation2/5

Many tools have overlapping purposes: ask_pipeworx and ask_pipeworx_beta are nearly identical, several prediction-market tools (bet_research, polymarket_edges, polymarket_arbitrage, polymarket_fill_risk, polymarket_kalshi_spread) cover similar territory, and research/verification tools (ask_pipeworx, ask_pipeworx_grounded, deep_research, validate_claim) blur together. The three sanctions tools are distinct, but the rest of the set creates frequent misselection risk.

Naming Consistency3/5

All tool names use snake_case, which is consistent, but the verb/noun ordering varies unpredictably (expectation vs entity_profile vs sanctions_screen vs scan_dependency). There is no dominant pattern like verb_noun, though names are readable.

Tool Count2/5

With 34 tools, the server is over-scoped, especially given its narrow 'Sanctions Screening' title. Many tools are duplicative (ask_pipeworx_beta duplicates ask_pipeworx; scan_competitor_ai_presence wraps ai_visibility_check), and the bulk are unrelated to the stated purpose. The count feels bloated.

Completeness3/5

The three sanctions tools (screen, entry, lists) cover the core read-only workflow well, but the server is mislabeled: most of the 34 tools are generic data/Pipeworx features unrelated to sanctions. For the broad data domain the set is fairly complete, but for the apparent 'Sanctions Screening' purpose it is both over- and under-scoped, with no bulk screening or list management.

Resources